In more than 3 million people worldwide treated for hypertension, ARBs were not only just as effective as ACE inhibitors at reducing the risk of major cardiovascular events, but also associated with a ...
November 4, 2011 (Tayside, Scotland) — With growing excitement over the emergence of transcatheter aortic-valve implantation (TAVI), might there still be room for an even less invasive option in ...
kidney Risk of mortality in HF patients with reduced kidney function taking ACE inhibitors and ARBs were evaluated. WASHINGTON, DC—According to data presented at the ACC.17 Scientific Session, ...
An ARB was as efficacious as an ACE inhibitor, but combination therapy failed to show any advantages. Angiotensin-converting-enzyme inhibitors lower the incidence of adverse cardiovascular events ...
Blockade of the renin-angiotensin-aldosterone-system with either an angiotensin receptor blocker (ARB) or angiotensin-converting enzyme (ACE) inhibitor provides similar protection from cardiovascular ...
This drug-utilization study in a prescription database of more than 50,000 patients analyzed compliance, persistence, and switching behavior for ACE inhibitors and ARBs. Although residual confounding ...
Although current guidelines recommend that ACE inhibitors and angiotensin-receptor blockers (ARBs) be used in high doses in patients with congestive heart failure, many CHF patients currently receive ...
PHILADELPHIA – Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) may represent effective migraine prophylactic treatments, according to the results of a ...
Do ACE inhibitors or angiotensin II receptor blockers (ARBs) offer renal protection to patients with diabetes or renal disease?— Negeen Farmand, PA-C, Los Angeles When should a clinician stop an ACE ...
In addition to their capacity to lower systemic blood pressure, angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs) are thought to have specific renoprotective ...
Renin-angiotensin-system (RAS) inhibitors have proven efficacy in patients who have heart failure with reduced ejection fraction (HFrEF). A registry study has now assessed the use of RAS inhibitors in ...